Financial highlights
·
Sales
growth in Pharmaceuticals and Consumer Healthcare; Vaccines sales flat
·
Pharmaceuticals
sales £4.2 billion +3% AER, +2% CER; Vaccines £1.7 billion +5% AER, flat at
CER; Consumer Healthcare £2.0 billion +5% AER, +2% CER
·
Improved
Total operating margin of 23.9% (+4.9 points, including 0.2 points currency
benefit) and EPS (24.8p), primarily reflecting reduced transaction-related
charges related to valuations of Consumer Healthcare and HIV businesses
·
Improved
Adjusted Group operating margin of 31.5% (+1.0 point, no currency effect)
primarily reflecting leverage from sales growth, focus on costs and benefits of
restructuring. Pharmaceuticals 34.0% (-0.3 points, no currency effect); Vaccines
41.3% (+1.6 points, including 0.3 points adverse currency effect); Consumer
Healthcare 20.0% (+3.9 points, including 1.3 points currency benefit) Click here to get full report
·
YTD
free cash flow £1.6 billion (9 months 2016: £1.3 billion)
·
19p
dividend declared for quarter. Continue to expect 80p for FY 2017
·
Guidance
for 2017 Adjusted earnings per share growth maintained at 3% to 5% CER
Product and pipeline highlights
·
New
product sales of £1.7 billion, +44% AER, +40% CER, driven by continued strong
performance from Tivicay/Triumeq in
HIV, Relvar/Breo Ellipta and Nucala in Respiratory and meningitis
vaccines
·
Trelegy Ellipta approved in the US for COPD and
positive opinion received in Europe. Positive results from landmark IMPACT
study show benefits of Trelegy Ellipta in
reducing COPD exacerbations compared to dual therapies
·
Shingrix vaccine for shingles approved in
US and Canada
·
Phase
III results for Nucala (mepolizumab)
in COPD published in New England Journal of Medicine with regulatory filings
planned for this year
·
In
Oncology, CHMP PRIME designation granted for 2857916 (BCMA antibody-drug
conjugate) for relapsed and refractory multiple myeloma and new data to be
presented at an upcoming scientific conference; option exercised from
Adaptimmune to develop T-cell therapy (NY-ESO-1) for multiple tumour
types